Myeloprotective effect of high dose medroxyprogesterone acetate (MPA)
Wils, J.A.
Chemioterapia International Journal of the Mediterranean Society of ChemoTherapy 7(1): 60-62
1988
ISSN/ISBN: 0392-906X PMID: 2967738 Document Number: 316252
Results of clinical studies in advanced and, recently, also in early breast cancer have shown a clear protective effect of high dose medroxyprogesterone acetate (MPA) on the bone marrow toxicity induced by chemotherapy. The underlying mechanism of this phenomenon is unsettled and in vitro studies have yielded contradictory results. The results of these clinical and in vitro studies are summarized. The myeloprotective effect may have important therapeutical implications.
Document emailed within 1 workday
Related Documents
Frick, J.; Bartsch, G.; Weiske, W.H. 1977: The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose Contraception 15(6): 669-677Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Pannuti, F.; Camaggi, C.M.; Strocchi, E.; Giovannini, M.; Di Marco, A.R.; Costanti, B. 1982: Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients Cancer Treatment Reports 66(12): 2043-2049
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Kjaer, M.; Frederiksen, P.L. 1986: High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase Ii study Cancer Treatment Reports 70(3): 431-432
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. 1989: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 161(4): 866-871
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323
Ylöstalo, P.; Vehaskari, A.; Kauppila, A. 1974: Effects of high-dose medroxyprogesterone given for endometrial carcinoma on serum proteins Annales Chirurgiae et Gynaecologiae Fenniae 63(2): 86-92
Cooper, A.J.; Sandhu, S.; Losztyn, S.; Cernovsky, Z. 1992: A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(10): 687-693
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Gai, L.; Zhang, J.; Zhang, H.; Gai, P.; Liu, Y. 2009: Effect of Depot Medroxyprogesterone Acetate (DMPA) on Bone Mineral Density in Women of Reproductive Age Journal of Reproduction and Contraception 20(1): 51-56
Formelli, F.; Ronchi, E.; Di Fronzo, G. 1985: Effect of medroxyprogesterone acetate on the growth of mouse transplanted tumors: relation with hormone sensitivity Anticancer Research 5(3): 313-319
Doody, K.; Bain, J. 1985: The effect of oral medroxyprogesterone acetate and methyltestosterone on sexual functioning in a male contraceptive trial Contraception 31(1): 65-70
Siriwongse, T.; Snidvongs, W.; Tantayaporn, P.; Leepipatpaiboon, S. 1982: Effect of depo-medroxyprogesterone acetate on serum progesterone levels when administered on various cycle days Contraception 26(5): 487-493
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102